Leading Heart Transplant Centers Convene in Houston for Picard Medical/ SynCardia's Total Artificial Heart Surgical Training
MWN-AI** Summary
Leading heart transplant centers convened in Houston for an exclusive training program focused on the SynCardia Total Artificial Heart, hosted by Picard Medical, Inc., the parent company of SynCardia Systems LLC. This invitation-only event took place at Houston Methodist Hospital, a recognized leader in cardiovascular care and a key player in the national heart transplant landscape. The training, scheduled for February 24, 2026, was designed to enhance the understanding and implementation of the SynCardia Total Artificial Heart, amidst the growing demand for advanced heart failure therapies.
The program united top cardiac surgeons and clinical teams from several renowned institutions, including Baylor St. Luke’s Medical Center and Texas Children’s Hospital. Led by Dr. Andre Simon, Vice President of Clinical Affairs at SynCardia, participants engaged in comprehensive instruction covering surgical techniques, patient selection, and clinical best practices. The curriculum emphasized a hands-on approach, combining classroom learning with practical surgical training, aiming to increase procedural consistency and optimize patient outcomes.
Dr. Simon emphasized the importance of peer-to-peer surgical education, noting that collaboration in specialized settings is vital for improving care for patients with severe heart failure. Patrick NJ Schnegelsberg, CEO of Picard Medical, elaborated on the initiative's goal to enhance clinical capabilities within U.S. heart centers, thereby broadening access to total artificial heart therapy.
This training initiative underscores Picard Medical’s commitment to supporting advanced heart failure programs across the country, with plans for additional training events in various markets. The Houston program exemplifies the focus on enhancing care for patients with end-stage biventricular heart failure and aims to increase the adoption of innovative heart technologies, reinforcing the significance of collaboration among leading heart treatment facilities.
MWN-AI** Analysis
The gathering of leading heart transplant centers in Houston for Picard Medical/SynCardia's Total Artificial Heart Surgical Training program underscores a strategic movement toward advancing heart failure treatment through innovative technology. As the only FDA-approved total artificial heart, SynCardia’s device represents a critical option for patients facing end-stage heart failure. The program, which features collaboration among top institutions like Houston Methodist and Baylor St. Luke’s, emphasizes continued education and adoption of this technology among clinical teams, which could lead to increased demand and utilization in the market.
For investors, this initiative is a noteworthy signal of growth potential for Picard Medical (NYSE American: PMI). The company’s focus on enhancing clinical capabilities through dedicated training fosters an environment geared toward higher implant volumes. Given the rising prevalence of advanced heart failure conditions and the ongoing need for effective solutions, Picard's strategy to create centers of excellence positions it favorably in a burgeoning market.
Additionally, the emphasis on hands-on training and peer-to-peer knowledge sharing is pivotal for ensuring best practices and improved patient outcomes. As heart transplant centers across the U.S. increasingly adopt the SynCardia Total Artificial Heart, expect a ripple effect of interest from healthcare providers and investors alike, potentially driving share prices upward in the long run.
Moreover, with plans for similar training initiatives in key markets, Picard Medical is poised to capture further market share, making it a compelling consideration for investors looking to align with a forward-looking healthcare company. As the heart failure treatment landscape evolves, keeping an eye on Picard’s developments and the broader acceptance of total artificial hearts will be essential for assessing investment opportunities in this dynamic sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Invitation-only program at Houston Methodist, one of the top heart transplant centers in the U.S., highlights the growing need for SynCardia Total Artificial Heart technology.
- Training initiative at Houston Methodist is expected to enable expanded adoption of the SynCardia Total Artificial Heart through further education.
TUCSON, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will host an exclusive, invitation-only “SynCardia Total Artificial Heart Training Village” at Houston Methodist Hospital on Tuesday, February 24th, 2026.
The “Training Village” will bring together leading cardiac surgeons and multidisciplinary clinical teams from Houston Methodist Hospital, Baylor St. Luke’s Medical Center, Memorial Hermann Texas Medical Center, and Texas Children’s Hospital for an advanced program focused on implantation techniques, patient selection, and clinical best practices for the SynCardia Total Artificial Heart.
The program will be led by Andre Simon, M.D., Vice President of Clinical Affairs at SynCardia, together with the SynCardia clinical team. Dr. Simon is an internationally recognized cardiac surgeon with extensive experience in mechanical circulatory support and total artificial heart implantation. The curriculum will combine focused classroom instruction with hands on surgical training to reinforce procedural consistency, clinical confidence, and optimal patient outcomes.
Andre Simon, M.D., commented, “Hands on, peer-to-peer surgical education is essential as total artificial heart therapy expands. Bringing experienced teams together in a focused setting strengthens best practices and ultimately improves care for patients facing advanced heart failure.”
Participants will also engage in collaborative discussions on surgical strategy, perioperative management, and long-term support, fostering knowledge sharing across Houston’s leading heart centers and reinforcing a shared commitment to advancing care for patients with end stage biventricular heart failure.
Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, added, “This initiative is part of our broader strategy to develop centers of excellence across key regions in the United States. By strengthening clinical capabilities and collaboration, we aim to expand patient access to total artificial heart therapy and support the continued growth of advanced heart failure programs.”
The Houston program reflects the Company’s ongoing commitment to clinical education, with additional training initiatives planned in key markets across the United States. The Houston region represents one of the largest advanced heart failure markets in the country, and expanding collaboration among high-volume transplant and mechanical circulatory support programs supports broader regional adoption of total artificial heart therapy. This approach aligns with Picard’s strategy to increase implant volumes and expand access at leading heart centers nationwide.
About Houston Methodist Hospital
Houston Methodist Hospital, located in the Texas Medical Center, is a nationally recognized academic medical center known for excellence in cardiovascular care, transplantation, and advanced surgical innovation.
About Participating Houston Heart Centers
Baylor St. Luke’s Medical Center, Memorial Hermann Texas Medical Center, and Texas Children’s Hospital are leading institutions within the Texas Medical Center, nationally recognized for cardiovascular medicine, transplantation, mechanical circulatory support, and complex heart care across adult and pediatric populations.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to measure the success and impact of the training initiative at Houston Methodist on the adoption of the SynCardia Total Artificial Heart technology?
What specific outcomes does Picard Medical Inc. PMI expect from the collaboration between Houston Methodist and other participating heart centers during the training program?
How will the training curriculum designed by Picard Medical Inc. PMI address the unique challenges faced by surgeons when implanting the SynCardia Total Artificial Heart in diverse patient populations?
Can you elaborate on the long-term vision of Picard Medical Inc. PMI for establishing centers of excellence beyond the Houston region in relation to total artificial heart therapy?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
11.56% G/L:
$1.205 Last:
66,661 Volume:
$1.14 Open:
